Liafensine

Liafensine

Clinical data
Routes of administration	Oral
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name 6-[(4S)-2-Methyl-4-(2-naphthyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-3-pyridazinamine
CAS Number	1198790-53-2
PubChem CID	58212050
ChemSpider	29271896
UNII	R34ID086Z6
KEGG	D10443
CompTox Dashboard (EPA)	DTXSID60152610
Chemical and physical data
Formula	C24H22N4
Molar mass	366.468 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C[C@H](C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4
InChI InChI=1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1 Key:VCIBGDSRPUOBOG-QFIPXVFZSA-N

Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder. Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse.

See also

• Amitifadine
• Ansofaxine